Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Vaccine for treating cancer made possible using Oxford COVID vaccine technology

Research from Jenner Institute and Ludwig Institute for Cancer Research has shown the technology behind the Oxford-AstraZeneca COVID-19 vaccine has potential in treating cancer. When tested in mice, the cancer vaccine increased levels of anti-tumour T cells infiltrating tumours and improved efficacy of cancer immunotherapy. Compared to immunotherapy alone, the combination with the vaccine showed a greater reduction in tumour size and improved survival of the mice.

Royal Society Africa Prize winner 2021

The Royal Society Africa Prize 2021 is awarded to Professor George Warimwe, Jenner Investigator, for his work on zoonoses vaccine development, capacity building in Africa, and his innovative research proposal. Professor Warimwe will be awarded a medal and a grant of £15,000 towards his research project at a symposium to be held at a future date.

Vaccine for TB receives a $1.5 million funding boost

The Oxford-run VALIDATE Network, co-directed by Jenner Investigator Prof Helen McShane, has received $1.5 million in funding for its tuberculosis vaccine work from the Bill & Melinda Gates Foundation. An effective vaccine for TB is one of the primary goals of the VALIDATE Network which aims to accelerate vaccine development for complex intracellular pathogens that are often neglected.

Making a billion doses of vaccine in 18 months: starting with two tablespoons

As the University was planning the first clinical trials for the COVID-19 vaccine, some began to wonder how to supply the vaccine to the world - if it worked. Although Oxford had the capacity to develop a COVID-19 vaccine, and clinical trials might take only a few months, manufacturing ‘at pandemic scale’ would take much longer. A group of University scientists had, however, worked on the problem for some time.

Applications now open for Vaccinology in Africa Course 2021

The course provides teaching in human and veterinary vaccinology by an exceptional faculty of academic and industrial speakers, with an emphasis on strengthening vaccine development and manufacturing autonomy in Africa. The course alternates between East and West Africa. In 2021, participation is for attendees working or studying in East Africa. Applications close 31 August.

African trial of novel HIV vaccine candidate starts

Professor Tomas Hanke, Professor of Vaccine Immunology at the Jenner Institute, and lead researcher on the trial, said: ‘This highly rational, bioinformatics-assisted, vaccine design addresses the enormous variability of HIV-1 - one of the greatest challenges to the development of an effective vaccine against HIV/AIDS.’

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

T-cell ‘training grounds’ behind robust immune system response seen in adenovirus vaccines

Adenovirus vaccine vectors, such as the ChAdOx1 nCov-19 construct which has risen to prominence as a major vaccine for COVID-19, may generate robust long-term immune system responses, according to scientists from the Universities of Oxford and the Cantonal Hospital St.Gallen, Switzerland.

HIV vaccine trial starts at Oxford

Vaccinations started today of a novel HIV vaccine candidate as part of a Phase I clinical trial in the UK. Professor Tomáš Hanke, Professor of Vaccine Immunology at the Jenner Institute and lead researcher on the trial, said: ‘An effective HIV vaccine has been elusive for 40 years. This trial is the first in a series of evaluations of this novel vaccine strategy in both HIV-negative individuals for prevention and in people living with HIV for cure.’

First trial participants vaccinated with Oxford COVID-19 variant vaccine

The University of Oxford in partnership with AstraZeneca began vaccinations on 27 June 2021 for a new phase in human trials to test a COVID-19 vaccine ‘AZD2816’ in volunteers against the B.1.351 variant of concern – commonly known as the Beta variant.

Mixed Oxford/Pfizer vaccine schedules generate robust immune response against COVID-19

Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study. Mixed schedules involving Pfizer-BioNTech and Oxford-AstraZeneca generate strong immune response against SARS-CoV2 spike IgG protein.

Delayed second dose and third doses of the Oxford-AstraZeneca vaccine lead to heightened immune response

Research on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose. Additionally, a third dose of the vaccine continues to boost antibodies against SARS-CoV-2.

Oxford University academics recognised in Queen’s Birthday Honours

The pioneering work of members of the University into tackling the Coronavirus pandemic has been recognised in The Queen's Birthday Honours List. The honorands include Jenner Institute researchers Sarah Gilbert, Catherine Green, Adrian Hill and Teresa Lambe.

Preliminary data suggests mixing Covid-19 vaccine increases reactogenicity

Researchers running the University of Oxford-led Com-COV study – launched earlier this year to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine – have today reported preliminary data revealing more frequent mild to moderate reactions in mixed schedules compared to standard schedules.

Professor Adrian Hill elected as Fellow of the Royal Society

Professor Adrian Hill is elected as Fellow of the Royal Society for his world-leading work in the design and development of new vaccines for globally important infectious diseases. He founded and directs the Jenner Institute at Oxford University.

Malaria vaccine becomes first to achieve WHO-specified 75% efficacy goal

Researchers from the University of Oxford and their partners have today reported findings from a Phase IIb trial of a candidate malaria vaccine, R21/Matrix-M, which demonstrated high-level efficacy of 77% over 12-months of follow-up.

Significant reductions in COVID-19 infections found after single dose of Oxford-AstraZeneca and Pfizer-BioNTech vaccine

COVID-19 infections fell significantly – by 65% percent - after a first dose of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines in this large community surveillance study.

Alternating vaccines trial expands to include two additional vaccines

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

Today, the medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine. Both the UK's Medicines and Healthcare products Regulatory Agency (MHRA) and the EU's European Medicines Agency have concluded that whilst there was a possible link from these very rare blood clots to the vaccine, the benefits of vaccination continue to outweigh the risks in all age groups, and have requested the product information is updated to mitigate further risks.

AstraZeneca publish primary analysis from US trial of coronavirus vaccine

Our partners AstraZeneca have today announced the high-level results from the primary analysis of their Phase III trial of the ChAdOx1 nCoV-19 coronavirus vaccine in the US. They confirm that the vaccine efficacy is consistent with the interim analysis results announced on Monday 22 March 2021.

Load More